Biggest changeResults of Operations The following table sets forth, for the periods presented, the consolidated statements of operations data, which is derived from the accompanying consolidated financial statements: Year Ended December 31, 2023 2022 $ Change % Change Revenue $ 743,952 $ 3,015,521 $ (2,271,569 ) -75 % Cost of revenues (1,852,208 ) (2,679,020 ) 826,812 -31 % Gross Margin (1,108,256 ) 336,501 (1,444,757 ) -429 % Operating expenses: Research and development 1,496,129 1,113,500 382,629 34 % Compensation and related expenses 2,854,494 1,644,861 1,209,633 74 % Professional fees 508,795 768,548 (259,753 ) -34 % General and administrative 2,675,202 1,565,723 1,109,479 71 % Total operating expenses 7,534,620 5,092,632 2,441,988 48 % Loss) from operations (8,642,876 ) (4,756,131 ) (3,886,745 ) 82 % Other income , net 539,354 66,164 473,190 715 % Loss) before income taxes (8,103,522 ) (4,689,967 ) (3,413,555 ) 73 % Provision for (benefit from) income taxes — — — 0 % Net loss $ (8,103,522 ) $ (4,689,967 ) $ (3,413,555 ) 73 % Year Ended December 31, 2023, as Compared to the Year Ended December 31, 2022 Our business has been focused on the development and commercialization of 374Water’s supercritical water oxidation (SCWO) systems.
Biggest changeResults of Operations The following table sets forth, for the periods presented, the consolidated statements of operations data, which is derived from the accompanying consolidated financial statements: Year Ended December 31, 2024 2023 $ Change % Change Revenues $ 445,445 $ 743,952 $ (298,507 ) -40 % Cost of revenues (1,358,152 ) (1,852,208 ) 494,056 -27 % Gross deficit (912,707 ) (1,108,256 ) 195,549 -18 % Operating expenses: Research and development 2,143,471 1,496,129 647,342 43 % Compensation and related expenses 3,685,007 2,854,494 830,513 29 % Professional fees 2,231,005 508,795 1,722,210 338 % General and administrative 3,831,068 2,675,202 1,155,866 43 % Total operating expenses 11,890,551 7,534,620 4,355,931 58 % Loss from operations (12,803,258 ) (8,642,876 ) (4,160,382 ) 48 % Other income, net 369,144 539,354 (170,210 ) -32 % Loss before income taxes (12,434,114 ) (8,103,522 ) (4,330,592 ) 53 % Provision for income taxes — — — 0 % Net loss $ (12,434,114 ) $ (8,103,522 ) $ (4,330,592 ) 53 % 36 Table of Contents Year Ended December 31, 2024, as Compared to the Year Ended December 31, 2023 Our business has been focused on the development and commercialization of 374Water’s supercritical water oxidation (SCWO) systems.
The Company has gained momentum on many promising leads which have been produced through early treatability studies but has not resulted in the sale of any AirSCWO units to this point. This has had a direct impact on our change in revenue year-over-year.
The Company has gained momentum on many promising leads which have been produced through early treatability studies but has not resulted in the sale of any additional AirSCWO units to this point. This has had a direct impact on our change in revenue year-over-year.
Recoverability of assets held and used is measured by a comparison of the carrying amount to the future undiscounted expected net cash flows to be generated by the asset. As of December 31, 2023 and 2022, there were no impairments. Inventory Inventories are stated at the lower of cost or net realizable value.
Recoverability of assets held and used is measured by a comparison of the carrying amount to the future undiscounted expected net cash flows to be generated by the asset. As of December 31, 2024 and 2023, there were no impairments. Inventory Inventories are stated at the lower of cost or net realizable value.
We believe the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the consolidated financial statements. 37 Table of Contents Long-Lived Assets The Company reviews long-lived assets, including property and equipment and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
We believe the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the consolidated financial statements. Long-Lived Assets The Company reviews long-lived assets, including property and equipment and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
There can be no assurance that these funds will be sufficient to finance our plan of operations and commercialize our systems or that we will be able to raise any necessary additional funds on a commercially reasonable basis or at all.
There can be no assurance that any additional funds raised will be sufficient to finance our plan of operations and commercialize our systems or that we will be able to raise any necessary additional funds on a commercially reasonable basis or at all.
Equipment sale related contract revenues are recognized in the proportion that contract costs incurred bear to total estimated costs. This method is used because management considers the input method to be the best available measure of progress on these contracts.
Equipment sale related contract revenues are recognized in proportion to the contract costs incurred compared to the total estimated costs to complete. This method is used because management considers the input method to be the best available measure of progress on these contracts.
When quantities on hand exceed estimated sales forecasts, we perform an analysis to determine if a write-down for such excess inventories is required. Once inventory has been written down, it creates a new cost basis for inventory that is not subsequently written up. Inventories are classified as current assets in accordance with recognized industry practice.
When quantities on hand exceed estimated sales or usage forecasts, we perform an analysis to determine if a write-down for such excess inventories is required. Once inventory has been written down, it creates a new cost basis for inventory. Inventories are classified as current assets in accordance with recognized industry practice.
We utilize third-party suppliers to produce our products. Costs associated with fabrication, and other costs associated with the manufacturing of products, are recorded as inventory. We periodically evaluate the carrying value of our inventories in relation to estimated forecasts of product demand, which takes into consideration the life cycle of product releases.
Costs associated with fabrication, and other costs associated with the manufacturing of products, are recorded as inventory. We periodically evaluate the carrying value of our inventories in relation to estimated forecasts of product demand, which takes into consideration the life cycle of product releases.
Costs associated with our sold unit have started to decline as we reach the end of our fabrication and testing, which have had a direct correlation to the reduced revenue recognized this year.
Costs associated with our sold unit have started to decline as we reach the end of our fabrication and testing, which have had a direct correlation to the reduced revenue recognized this year under our percentage of completion revenue recognition method.
Our other income increased to $539,354 during the year ended December 31, 2023, as compared to $66,164 in the same period of 2022, which is a result of the interest income we earned on our interest-bearing cash accounts that we opened in June 2023. We had previously held any excess funds in an investment account.
Our other income decreased to $369,144 during the year ended December 31, 2024, as compared to $539,354 in the same period of 2023, which is a result of the interest income we earned on our interest-bearing cash accounts that we opened in June 2023. We had previously held any excess funds in an investment account.
We generated $743,952 and $3,015,521 in revenue from manufacturing assembly services and from treatability study services during the years ended December 31, 2023, and 2022, respectively. During 2023, we reached fewer milestones and thus incurred less direct contract costs.
We generated $445,445 and $743,952 in revenue from manufacturing assembly services and from treatability study services during the years ended December 31, 2024, and 2023, respectively. During 2024, we reached fewer milestones and thus incurred less direct contract costs.
The Company generates revenue from the sale of equipment (AirSCWO units) and services, specifically the completion of treatability studies. In the case of equipment revenues, the Company’s performance obligations are satisfied over time over the life of the contract which are typically fixed price contracts.
The Company generates revenue from the sale of equipment (AirSCWO systems) and services, specifically the completion of treatability studies and demonstration services of various types of waste streams. In the case of revenues from AirSCWO systems, the Company’s performance obligations are satisfied over time over the life of the contract, which is currently a long-term fixed price contract.
Revenue Recognition The Company follows the revenue standards of Codification (ASC) Topic 606: “Revenue from Contracts with Customers (Topic 606).” The core principle of this Topic is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
Based on our evaluation, we estimated an inventory allowance of $50,000 and $0 at December 31, 2024 and December 31, 2023, respectively. 33 Table of Contents Revenue Recognition The Company follows the revenue standards of Codification (ASC) Topic 606: “Revenue from Contracts with Customers (Topic 606).” The core principle of this Topic is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
During the year ended December 31, 2023, cash provided by investing activities was $1,851,717, an increase of $4,012,008, as compared to cash used in investing activities of $2,160,291 during the year ended December 31, 2022.
During the year ended December 31, 2024, cash used by investing activities was $653,544, an increase of $2,505,261, as compared to cash provided by investing activities of $1,851,717 during the year ended December 31, 2023.
During the year ended December 31, 2023, cash used in operations was $9,034,987, an increase of $4,086,319 as compared to $4,948,996 during the year ended December 31, 2022.
During the year ended December 31, 2024, cash used in operations was $10,589,735, an increase of $1,554,748 as compared to $9,034,987 during the year ended December 31, 2023.
During the year end December 31, 2023, we raised approximately $13.4 million of net proceeds through this ATM. We have financed our operations since inception principally through the sale of debt and equity securities and revenues. As of December 31, 2023, we had working capital of $13,528,176 compared to working capital of $7,060,511 as of December 31, 2022.
We have financed our operations since inception principally through the sale of debt and equity securities and revenues. As of December 31, 2024, we had working capital of $11,760,131 compared to working capital of $13,528,176 as of December 31, 2023.
The revenue standard does not provide guidance on the accounting for onerous contracts or onerous performance obligations. US GAAP contains other applicable guidance on the accounting for onerous contracts, and those requirements should be used to identify and measure onerous contracts. 38 Table of Contents Our equipment manufacturing contract is a fixed price contract.
GAAP contains other applicable guidance on the accounting for onerous contracts, and those requirements should be used to identify and measure onerous contracts. The Company’s outstanding equipment manufacturing contract on our sold unit is a fixed price contract (“Equipment Sale Contract”).
Cash Flows The following table presents our cash flows for the periods presented: Year Ended December 31, 2023 2022 $ Change Cash used in operating activities $ (9,034,987 ) $ (4,948,668 ) $ (4,086,319 ) Cash provided by (used in) investing activities 1,851,717 (2,160,291 ) 4,012,008 Cash used in financing activities 13,578,938 25,049 13,553,889 Effect of exchange rates on cash 2,799 (328 ) 3,127 Net cash increase (decrease) 6,398,467 (7,084,238 ) 13,482,705 As of December 31, 2023, cash on hand was $10,445,404, an increase of $6,398,467, or 158%, as compared to $4,046,937 as of December 31, 2022.
Cash Flows The following table presents our cash flows for the periods presented: Year Ended December 31, 2024 2023 $ Change Cash used in operating activities $ (10,589,735 ) $ (9,034,987 ) $ (1,554,748 ) Cash provided by (used in) investing activities (653,544 ) 1,851,717 (2,505,261 ) Cash provided by financing activities 11,449,519 13,578,938 (2,129,419 ) Effect of exchange rates on cash — 2,799 (2,799 ) Net cash increase (decrease) 206,240 6,398,467 (6,192,227 ) 38 Table of Contents As of December 31, 2024, cash on hand was $10,651,644, an increase of $206,240, or 2%, as compared to $10,445,404 as of December 31, 2023.
We have an at-the-market (ATM) equity offering under which we may issue up to $100 million of common stock, which is currently effective and under which we commenced selling shares at the end of January 2023, and which will remain available to us in the future.
Substantial net losses are expected until we are able to generate sufficient cash flows from the sale of our AirSCWO systems, treatability studies and Waste Destruction Services, as to which there can be no assurance. 37 Table of Contents Liquidity and Capital Resources We have an at-the-market (ATM) equity offering under which we may issue up to $100 million of common stock, which is currently effective and under which we commenced selling shares at the end of January 2023, and which will remain available to us in the future.
This increase in working capital is due primarily to the at-the-market common stock offering that raised additional capital. We believe that these funds will satisfy our working capital needs for the next 12 months from the report date.
We do not believe that these funds will satisfy our working capital needs for the next 12 months from the report date and we will need to raise additional capital to implement our business plan.
Our compensation and related expenses increased to $2,854,494 during the year ended December 31, 2023, as compared to $1,644,861 in the same period of 2022. This is a deliberate step in our strategic growth plan to ensure we have sufficient personnel to support our upcoming growth and sales pipeline.
Our compensation and related expenses increased to $3,685,007 during the year ended December 31, 2024, as compared to $2,854,494 in the same period of 2023.
Services revenues are recognized when all five revenue recognition criteria have been completed which is generally when we deliver a completed report to the customer. We also record as revenue all amounts billed to customers for shipping and handling costs and record the actual shipping costs as a component of cost of revenues.
Services revenues, from treatability studies, are recognized when all five revenue recognition criteria have been completed which is generally when the Company has delivered a completed treatability study report to the customer.
Stock-Based Compensation We account for stock-based compensation based on ASC Topic 718-Stock Compensation which requires expensing of stock options and other share-based payments based on the fair value of each stock option awarded. The fair value of each stock option is estimated on the date of grant using the Black-Scholes valuation model.
The fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock options.
Our research and development expenses increased to $1,496,129 during the year ended December 31, 2023, as compared to $1,113,500 in the same period of 2022, primarily attributed to our development of the HEC-Prime engine. The solution consists of five pistons and turbines that collect the high-pressure mix gas (steam) to rotate and spin a shaft connected to a generator unit.
Our research and development expenses increased to $2,143,471 during the year ended December 31, 2024, as compared to $1,496,129 in the same period of 2023, primarily due to the increase in engineering expenses and expenses stemming from our continued efforts to commercialize our systems.
Our general and administrative expenses increased to $2,675,202 during the year ended December 31, 2023, as compared to $1,565,723 in the same period of 2022, primarily because of increased personnel to facilitate the commercialization of our systems which has led to increased insurance costs, stock-based compensation expense for option grants to our hired employees, restricted stock grants to certain key executives, travel expenses and marketing and advertising expenses.
Further, we incurred additional professional fees for executive search services related to the finding and hiring of certain executives we have hired in 2024. Our general and administrative expenses increased to $3,831,068 during the year ended December 31, 2024, as compared to $2,675,202 in the same period of 2023.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Not required for smaller reporting companies.
The decrease in cash provided by financing activities was due to more capital being raised in 2023 via our ATM compared to the cash raised in 2024 through our ATM and director offering completed in November 2024. ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Not required for smaller reporting companies.
The increase in cash provided by investing activities is due to proceeds received from our held to maturity investment of $1,963,432 and a decline in purchases of long-lived assets of $85,144 in 2023 compared to 2022. Cash used in investing activities during the year ended December 31, 2022 primarily related to the purchase of the investment of $1,963,432.
In 2023, we received $1,963,432 in proceeds from the sale of investments, which were not received in 2024. During the year ended December 31, 2024, cash provided by financing activities was $11,449,519, a decrease of $2,129,419 compared to the same period in 2023.